Nanoform is delighted to announce the initiation of a technology evaluation of Nanoform’s Proprietary CESS® Technology across a range of AstraZeneca’s proprietary pharmaceutical products.
The initiation of this study is to assess the added value that Nanoform’s proprietary technology could deliver across the pharmaceutical value chain.
We have always believed that our technology has significant value to offer the Pharma industry, particularly in reducing clinical attrition rates by nanonizationTM to increase dissolution rates of poorly soluble APIs and overcome significant bioavailability challenges, as evidenced by the work conducted between us and our pharmaceutical partners. Producing tailored nanoparticles
